, GlobeNewswire
Santhera Statement
Santhera Pharmaceuticals Holding AG /
Santhera Statement
Verarbeitet und übermittelt durch Hugin.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Liestal, Switzerland, January 25, 2011 - Santhera Pharmaceuticals (SIX: SANN)
announced today that - as part of its ordinary course of business - it is
constantly evaluating its strategic options. As part of such process the company
has had a high level dialogue with Newron Pharmaceuticals S.p.A. The
continuation, content and outcome of such dialogue cannot be predicted. No
further comments will be made.
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of severe neuromuscular diseases, an area of high
unmet medical need which includes many orphan indications with no current
therapy. Santhera's first product, Catena®, to treat Friedreich's Ataxia is
marketed in Canada. For further information, please visit www.santhera.com.
Catena® is a trademark of Santhera Pharmaceuticals.
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
--- Ende der Mitteilung ---
Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Schweiz
ISIN: CH0027148649;
Santhera Statement:
http://hugin.info/137261/R/1482374/417700.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1482374]
Santhera Statement
Verarbeitet und übermittelt durch Hugin.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Liestal, Switzerland, January 25, 2011 - Santhera Pharmaceuticals (SIX: SANN)
announced today that - as part of its ordinary course of business - it is
constantly evaluating its strategic options. As part of such process the company
has had a high level dialogue with Newron Pharmaceuticals S.p.A. The
continuation, content and outcome of such dialogue cannot be predicted. No
further comments will be made.
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of severe neuromuscular diseases, an area of high
unmet medical need which includes many orphan indications with no current
therapy. Santhera's first product, Catena®, to treat Friedreich's Ataxia is
marketed in Canada. For further information, please visit www.santhera.com.
Catena® is a trademark of Santhera Pharmaceuticals.
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
--- Ende der Mitteilung ---
Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Schweiz
ISIN: CH0027148649;
Santhera Statement:
http://hugin.info/137261/R/1482374/417700.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1482374]
Relevante Links: Santhera Pharmaceuticals Holding AG